Mr. Peter Carre: Chairman 
(AB (Harvard), JD (Boston))
Peter is an experienced lawyer, company advisor and director with a strong track record in commercialising innovative med/bio-technologies. Peter has developed many companies out of research institutes and universities, raised capital, and led senior technology management teams. He received a lifetime achievement award for corporate governance from the AICD, was an APEC Summit (Shanghai) keynote speaker on Medtech investing in Asia-Pacific, a former Garvan Institute of Medical Research Commercialisation Director and a co-founder of Xcelerator, Australia's first life sciences incubator which listed several Med/Bio-tech companies on the ASX. Peter graduated from Harvard College and Boston University Law School.


Dr. Wayne Markman: CEO 
(BEcon (Macalester), MBA (Harvard), BChiro & MChiro (Macquarie))
Wayne is an experienced healthcare CEO, former corporate finance and venture capital professional and a qualified Doctor of Chiropractic Medicine. He has led several early-stage ventures in commercialising medical technologies including the consolidation and sale of Australian dental practices and a national, corporate-based musculoskeletal therapeutic business. Wayne was previously a Director at Credit-Suisse where he structured and managed M&A and capital market transactions in the media/telco and pharmaceutical sectors. He has previously taught financial restructuring in the Macquarie Applied Finance master's degree and currently teaches investment management at University Technology Sydney. Wayne graduated from Macalester College in St. Paul, Minnesota, The London School of Economics, Harvard Business School and Macquarie University.


AnnDr. Ann Liebert: Chief Scientist 
(B.App Science - Physio, PhD (USYD))
Ann is a world-renowned researcher in Medical Photobiomics, Coordinator of Photomolecular Research, San Hospital, a qualified Physiotherapist and Adjunct Senior Lecturer Department of Medicine at The University of Sydney. Research projects include metabolic disease/pre-diabetes insulin resistance trial-of-concept case studies and multi-centre Parkinson's translational trials - in Sydney, Brisbane and Adelaide. Ann was a keynote speaker at the International Society for Optics and Photonics (SPIE Photonics West) in San Francisco in February 2020. Ann is currently leading the development of SYMBYX's therapies for neurodegenerative and obesity-related disorders, commencing with a system for alleviating Parkinson’s-related symptoms. Ann is a graduate of the University of Sydney. 


Dr. Brian Bicknell: Microbiologist 
(B.Science (USYD), PhD (UNSW))
Brian was formerly an Honorary Fellow of Faculty Health Sciences at ACU and a Visiting Research Fellow at Australasian Research Institute, San Hospital. Brian pioneered the fundamental research investigating the effect of light on the microbiome, both originally in mice models and recently in human models. Brian has co-published many research papers on Photobiomodulation and Photobiomics with Dr. Liebert. Brian presented the first report of results of our Parkinson’s trials at the International Society for Optics and Photonics (SPIE Photonics West) in San Francisco in February 2020. Brian is integrally involved in conducting the Parkinson's and Obesity trials for SYMBYX and in furthering the studies into the effect of light on the microbiome. Brian graduated from the the University of Sydney and UNSW.


Emeritus Professor Branko Celler: Scientific and Regulatory Advisor 
(PhD, FIEEE, FTSE, FACHI, FIEA Aust, IEEE (John Hopkins. UNSW))
Branko is an internationally recognised biomedical researcher with vast experience in developing biomedical devices for chronic disease management at home. He is widely regarded as a pioneer in the Australian telehealth industry. In addition to his distinguished academic career, Branko has managed several biomedical products through the regulatory process and on to international distribution. Branko is also a Fellow of several Societies including the Australian Academy of Technology and Engineering and the IEEE, the world’s largest professional body. He has raised over $18 million from industry and nationally competitive grants. Branko graduated from UNSW and Johns Hopkins University in Baltimore, Maryland. 


Professor Michael R. Hamblin: Scientific Advisory Board
(PhD (Trent))
Mike’s international reputation, thought leadership and research output in the field of Medical Photobiomodulation is unrivalled. He was previously Principal Investigator at Wellman Center for Photomedicine (Mass. General Hospital), Associate Professor Dermatology at Harvard Medical School and part-time faculty member at University of Johannesburg, South Africa. Mike’s research interests include photodynamic therapy, photobiomodulation, drug delivery, nanomedicine, and tissue engineering. His research program was supported by NIH, CDMRP, USAFOSR and CIMIT. He has published over 500 peer-reviewed articles, over 150 conference proceedings, book chapters and International abstracts and holds 10 patents. He is currently Editor-in Chief of “Photobiomodulation, Photomedicine and Laser Surgery”. Mike is Associate Editor for 10 journals, on the editorial board of a further 20 and has an  h-factor 106 with > 45,000 citations. He has authored/edited 25 textbooks on PDT and photomedicine including 13 SPIE proceedings. Dr. Hamblin was elected as a Fellow of SPIE in 2011, received the 1st Endre Mester Lifetime Achievement Award from NAALT in 2017, the Outstanding Career Award from the Dose Response Society, and the 1st Ali Javan award for Photobiomodulation Basic Science Research from WALT in 2018. Mike graduated from Trent University, England, with a PhD in organic chemistry.


Professor Hosen Kiat: Scientific Board
Hosen is a Professor of Cardiology, Department of Clinical Medicine at Macquarie University. He was one of the original founding academics of Macquarie University Hospital and Head of the Medicine Discipline from 2007-2015. Professor Kiat is also conjoint Professor of Medicine, UNSW and adjunct Professor of Molecular Imaging and Nuclear Medicine, School of Dentistry and Health Sciences at Charles Stuart University, NSW. Professor Kiat did his medical internship and residency at the Alfred Hospital, Melbourne, and has completed internal medicine and cardiology fellowship training at the Alfred & Austin Hospitals, Melbourne and Westmead Hospital, Sydney. He was AHA Research Fellow at Cedar Sinai Medical Centre, UCLA School of Medicine and went on to be appointed as Staff Cardiologist and Director of Cardiac Imaging Research. Dr Kiat obtained Diplomate of American Boards in Internal Medicine, Nuclear Medicine Cardiovascular Disease-Subspecialty Cardiac CT. Hosen's research activities have an emphasis on medical imaging and preventative medicine. Kiat has published over 275 journal papers, received 12,991 citations and received over $7M in research-funding. Prof Hosen advises SYMBYX's clinical trials with a particular focus on developing cardio-vascular-related therapies. He graduated from Monash University and UNSW.